Dr. Martens (DOCS) reported Q2 2026 earnings, with an 8.41% stock surge despite a slight revenue decline. The company's consumer-first pivot and cost control drove significant profit growth.
Revenue fell 1.4% on a constant currency basis. The stock trades at $19.58, still undervalued per Bond.az analysis.
Market cap is $3.62 billion, with a 89% gross profit margin and 16.4% return on assets.
CEO Kenny Wilson highlighted the consumer-first strategy: "Our focus on revenue quality and cost control positions us well for growth." CFO Giles Porter noted the 61% profit increase reflects successful execution.
The company plans expansion in the Americas and APAC, with a capital-light model in new markets.
